PT-141 (Bremelanotide): A Laboratory Research Guide to Melanocortin Receptor Signaling
PT-141, also known as bremelanotide, is a synthetic cyclic peptide investigated in melanocortin receptor research. It is structurally related to α-melanocyte-stimulating hormone (α-MSH) analogues and has been studied as a pharmacological probe for examining melanocortin receptor signaling, central nervous system pathways, receptor selectivity, and downstream neurochemical responses.
This guide focuses on the compound from a laboratory research perspective, with emphasis on molecular structure, receptor pharmacology, experimental models, analytical characterization, and published research.
All information presented here is strictly for scientific and laboratory research purposes.
What Is PT-141 (Bremelanotide)?
PT-141 is a synthetic cyclic heptapeptide with the sequence:
Ac-Nle-cyclo(Asp-His-D-Phe-Arg-Trp-Lys)-OH
It was developed through research involving melanocortin peptide analogues, including Melanotan II. Structural modifications within this peptide family have allowed researchers to investigate how specific molecular changes alter receptor affinity, selectivity, stability, and downstream signaling.
PT-141 is commonly studied as a melanocortin receptor agonist and is particularly relevant to experimental research involving the MC3R and MC4R receptor subtypes.
The Melanocortin Receptor System
The melanocortin system consists of several G protein-coupled receptor subtypes designated MC1R through MC5R.
These receptors exhibit different tissue-distribution patterns and participate in distinct signaling networks.
PT-141 research commonly focuses on:
- MC3R (Melanocortin 3 Receptor)
- MC4R (Melanocortin 4 Receptor)
Both receptors are expressed in central nervous system regions and are used in experimental models designed to characterize melanocortin signaling.
Because receptor expression varies by tissue, species, and experimental model, findings should be interpreted within the specific conditions of each study.
Mechanism of Action
PT-141 is investigated as a melanocortin receptor agonist.
MC3R and MC4R are G protein-coupled receptors that can activate intracellular signaling following ligand binding.
A simplified experimental pathway is:
PT-141 → melanocortin receptor activation → G-protein signaling → adenylyl cyclase activation → changes in intracellular cAMP
Researchers may examine downstream endpoints such as:
- Intracellular cAMP
- Protein kinase A activity
- Receptor internalization
- Transcription-factor activity
- Neuronal firing patterns
- Neurotransmitter-associated signaling
- Receptor desensitization
- Gene-expression changes
The magnitude and direction of these responses depend on receptor subtype, receptor density, cell type, ligand concentration, exposure duration, and experimental design.
MC4R Research
MC4R is widely studied in neurobiology because of its distribution within hypothalamic and other central nervous system regions.
PT-141 may be used in experimental models to investigate:
- MC4R activation
- Receptor-binding characteristics
- Intracellular signaling
- Neural-circuit responses
- Neurotransmitter-associated pathways
- Receptor-dependent behavioral endpoints in animal models
- Interactions between melanocortin and dopaminergic signaling networks
When behavioral endpoints are used in animal studies, they should be described as model-specific observations rather than extrapolated to human outcomes.
MC3R Research
MC3R provides another important target for melanocortin research.
Experimental studies may examine:
- MC3R ligand binding
- Receptor-selective signaling
- cAMP responses
- Tissue-specific receptor expression
- Central and peripheral signaling networks
- Interactions with other melanocortin receptor subtypes
Comparative analysis of MC3R and MC4R responses can help researchers characterize receptor subtype contributions within a given model.
Neurochemical and CNS Research
One of the major laboratory applications of PT-141 involves investigation of neural signaling.
Researchers may examine how melanocortin receptor activation interacts with neurochemical pathways in selected brain regions.
Potential experimental endpoints include:
- Dopamine-associated signaling
- Neuronal activation markers
- Immediate-early gene expression
- Receptor localization
- Electrophysiological activity
- Neurotransmitter release
- Hypothalamic signaling
- Mesolimbic pathway activity
Such research can help clarify relationships between melanocortin receptors and broader neural signaling networks.
Behavioral Models
Published animal studies involving melanocortin agonists have used behavioral assays as experimental endpoints.
These may involve standardized observations of receptor-dependent behavioral responses following controlled experimental exposure.
For an RUO context, these findings are best described as tools for investigating:
- Neural-circuit activation
- Receptor-mediated behavior
- Pharmacological specificity
- Dose-response relationships within validated animal models
- Receptor antagonism and pathway confirmation
Behavioral findings from animals should not be presented as evidence of a corresponding human effect or intended use.
Inflammation and Experimental Stress Models
Melanocortin receptors have also been studied in experimental models involving inflammatory signaling and physiological stress.
Researchers may investigate endpoints such as:
- Cytokine expression
- NF-κB-associated pathways
- Oxidative-stress markers
- Tissue injury biomarkers
- Receptor-dependent inflammatory signaling
- Cellular stress-response pathways
Some published work has examined melanocortin receptor signaling in animal models of hemorrhagic or systemic physiological stress.
These studies represent preclinical experimental observations and should not be interpreted as establishing medical, therapeutic, or protective effects of an RUO material.
Receptor Pharmacology
PT-141 can be useful in receptor pharmacology experiments designed to characterize melanocortin receptor activity.
Common laboratory approaches include:
Binding Assays
Radioligand or competitive binding assays may be used to evaluate receptor affinity and ligand competition.
Functional Assays
Cells expressing selected melanocortin receptor subtypes can be used to measure downstream signaling such as cAMP production.
Antagonist Studies
Receptor antagonists may be incorporated to help determine whether an observed response is mediated through a specific melanocortin receptor subtype.
Receptor Expression Studies
qPCR, Western blotting, immunohistochemistry, or related techniques may be used to characterize MC3R or MC4R expression within experimental tissues.
Analytical Characterization
The identity and integrity of peptide research materials are important variables in laboratory studies.
Depending on the experimental objective, analytical characterization may include:
- Molecular identity
- Molecular mass
- Amino-acid sequence confirmation
- Chromatographic purity
- Peptide integrity
- Degradation products
- Solubility under defined experimental conditions
- Stability during storage and handling
Common analytical techniques may include:
- High-performance liquid chromatography (HPLC)
- Liquid chromatography-mass spectrometry (LC-MS)
- Mass spectrometry
- Amino-acid analysis
- Peptide mapping
Stability and Laboratory Handling
Peptide stability can be influenced by multiple environmental and experimental variables.
Researchers should consider:
- Temperature
- Light exposure
- Moisture
- Oxidation
- Buffer composition
- pH
- Repeated temperature cycling
- Storage duration
- Adsorption to laboratory surfaces
- Sample handling
Storage and handling conditions should follow validated laboratory protocols and product-specific analytical documentation where available.
Rather than relying on generalized consumer-style handling instructions, researchers should establish conditions appropriate to the assay design, material specifications, and analytical requirements of the experiment.
Common Laboratory Research Applications
PT-141 may be incorporated into research involving:
Melanocortin receptor pharmacology: Characterization of MC3R and MC4R agonist activity, receptor affinity, and signaling.
Neuroscience: Investigation of melanocortin-dependent neural pathways and receptor-associated neurochemical signaling.
Cell signaling: Measurement of cAMP and other intracellular responses following receptor activation.
Behavioral pharmacology: Examination of receptor-dependent behavioral endpoints in validated animal models.
Receptor selectivity: Comparison of signaling responses across melanocortin receptor subtypes.
Inflammatory signaling: Investigation of melanocortin receptor pathways in controlled cellular or animal-model systems.
Experimental Design Considerations
Important variables in PT-141 research may include:
- Cell or tissue type
- Species and model selection
- Receptor subtype expression
- Appropriate positive and negative controls
- Compound identity and purity
- Experimental concentration
- Exposure duration
- Assay sensitivity
- Receptor antagonists
- Biological and technical replicates
- Statistical methodology
Researchers should avoid assuming that responses observed in one model will reproduce across other cell types, tissues, species, or experimental conditions.
Published Research
The following publications provide background on PT-141, bremelanotide, and melanocortin receptor pharmacology:
- Shadiack, A. M., et al. (2007). Research concerning melanocortins and central melanocortin receptor pharmacology. Current Topics in Medicinal Chemistry.
- Hadley, M. E., & Dorr, R. T. (2006). Research reviewing melanocortin receptor agonists and their pharmacological characteristics. Peptides/Peptide Science literature.
- King, S. H., et al. (2005). Research concerning bremelanotide pharmacology and clinical development. Expert Opinion on Investigational Drugs.
- Pfaus, J. G., et al. (2004). Experimental animal research involving melanocortin receptor agonism and behavioral endpoints. Proceedings of the National Academy of Sciences.
- Molinoff, P. B., et al. (2003). Research characterizing PT-141 and melanocortin receptor pharmacology. Annals of the New York Academy of Sciences.
- Guarini, S., et al. (2004). Research examining melanocortin receptors in experimental inflammatory signaling. European Journal of Pharmacology.
Published literature may include animal studies, mechanistic studies, and human clinical investigations involving bremelanotide. Such publications are cited solely to describe the scientific history and pharmacology of the molecule. They do not establish an intended use for any PeakForce Labs research material.
Research Use Only
PT-141 (Bremelanotide) offered by PeakForce Labs is intended strictly for laboratory research use only (RUO).
It is not intended for human or veterinary use, personal use, medical or therapeutic use, diagnostic use, or administration to humans or animals.
PeakForce Labs does not provide dosing, administration, injection, ingestion, personal reconstitution, or treatment instructions for research materials.
Researchers are responsible for ensuring that acquisition, storage, handling, experimentation, and disposal are conducted in accordance with applicable institutional policies, validated laboratory procedures, and federal, state, and local requirements.